1000%. The insidious thing about Amarin, is that stock grants are technically tied to performance, but they set the performance hurdle artificially low in terms of sales, rather than the appropriate barometer which should be stock price. Amarin's method might be standard across many companies (I have not studied the issue), but whether it is or not, does not make it right.
Bottom line: If the company was truly ethical in its actions, rather than its platitudes, Directors would be paid a reasonable stipend for their service, and the big dollars in terms of stock grants are directly tied to the benefit to the shareholders as exemplified by the stock price.
"Oh marjac, we won't be able to get the best and brightest." Ya right. How's the current structure working out for shareholders? To the extent someone still wishes to be an apologist for management, take the marjac four-part quiz:
1) What was the stock price in the aftermath of Reduce-It?
2) What was the stock price after expanded label approval?
3) What was the stock price after the 3/30/2022 Dusaster?
4) What is the stock price now?
As the great Bill Parcells said, "You are what your stock price says you are."
News 
Market Data 
Discover 
AI
